DOCSLIB.ORG

Inhibitory Effect of Bromazepam on Basal and Betazole-Stimulated Gastric Acid Secretion in Man

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibitory Effect of Bromazepam on Basal and Betazole-Stimulated Gastric Acid Secretion in Man Gut: first published as 10.1136/gut.15.2.116 on 1 February 1974. Downloaded from Gut, 1974, 15, 116-120 Inhibitory effect of bromazepam on basal and betazole-stimulated gastric acid secretion in man G. STACHER1 AND DORIS STARKER From the Research Laboratory of the First Surgical and the Psychiatric University Clinic, Vienna, Austria SUMMARY Basal, as well as betazole-stimulated gastric acid secretion in man is reduced after the intravenous administration of bromazepam. In subjects staying awake, this reduction is limited to the first two 15-minute periods. The reduction is highly significant in subjects who fall asleep after receiving the drug. Natural sleep causes the same depression. The low level of acid secretion is maintained until the subjects are awakened when there is a sharp and highly significant rise. Acid secretion in subjects who fall asleep after the simultaneous administration of betazole and brom- azepam is significantly higher than after the administration of bromazepam alone. Sleep causes a much greater depression of basal and betazole-stimulated acid secretion than does the benzodiaze- pine itself. Acid secretion was measured by continuous intragastric titration and a pH-sensitive endoradio- sonde. 'Maximal' acid output in response to an augmented effect of another benzodiazepine, bromazepam, with histamine test, betazole, or pentagastrin is known or without sleep, on basal and betazole-stimulated to be affected by certain drugs and by vagotomy. secretion in man. Very little is known about the influence of the level http://gut.bmj.com/ ofcentral and autonomic activity. Sleep was reported Methods to cause no significant change from the waking level on unstimulated gastric secretion (Sandweiss, MEASUREMENT OF GASTRIC ACID SECRETION Friedman, Sugarman, and Podolsky, 1946; Wolf and We used the method of continuous intragastric Wolff, 1947; Levin, Kirsner, Palmer, and Butler, titration and an endoradiosonde (Heidelberg capsule) 1948; Reichsman, Cohen, Colwill, Davis, Kessler, as an intragastric pH sensor (Stavney, Hamilton, Shepardson, and Engel, 1960) or to cause stimulation Sircus, and Smith, 1966). The acidic gastric contents on October 1, 2021 by guest. Protected copyright. (Johnston and Washeim, 1924). Only a study in a were neutralized by oral administration of 5 ml of a child with a gastric fistula showed diminished gastric molar potassium bicarbonate solution. When the secretion during sleep (Engel, Reichsman, and original acidic pH was again reached a further dose Segal, 1956). Several reports exist on the influence of bicarbonate was given and this procedure was of anaesthesia on histamine-stimulated gastric acid continued until the experiment was ended. The secretion. In dogs secretion was found to be reduced times between the two titrations were measured. As (Marks, Komarov, and Shay, 1958; Skyring et al, 5 m-equiv KHCO3 reacts with 5 m-equiv HCl it 1961; Powell and Hirschowitz, 1967) or stimulated was assumed that during one neutralization time (Schachter, 1949) and in man Merendino (1948) also 5 m-equiv HCl was produced. Acid output was observed a further stimulation. calculated as milliequivalents per 15 minutes. Sleep induced by sodium pentobarbital was reported to have no influence on histamine-stimula- APPARATUS ted acid secretion (Reichsman et al, 1960). More The endoradiosondes (Heidelberg capsule) are recently, the tranquillizer diazepam was shown to commercially available pH-sensitive radio pills. diminish basal acid secretion (Berner, Neumayr, and The signals from the pills are received by an antenna Stacher, 1971; Birnbaum, Karmeli, and Makonnen, system and fed into a modified radio receiver able 1971). The purpose of this study was to assess the to measure not only pH changes as expressed in 'Present address: I. Chirurgische Universit5tsklinik, 1090 wien, Alserstr. 4, Austria. frequency shifts but also the variations in electro- Received for publication 3 December 1973. magnetic field strength, which shows the movements 116 Gut: first published as 10.1136/gut.15.2.116 on 1 February 1974. Downloaded from Inhibitory effect ofbromazepam on basal and betazole-stimulated gastric acid secretion in man 117 pH7 - pHi - 5 minutes Fig 1 Continuous intragastric titration with the pH-sensitive endoradiosonde. Upper trace, pH, lower trace, variation ofelectromagnetic field strength as measure ofgastric motility. Oral administration of5 mt 1 m KHCO3 is indicated by an arrow (t). of the pills in the stomach (fig 1). The pH and field subjects); (4) administration of 0 1 mg per kg body strength were recorded on a two-channel writing weight bromazepam intravenously, and after injec- system. All measurements were carried out in a tion, the subjects were kept awake (10 tests on six screened room to avoid interference from high subjects); (5) administration of 0.1 mg per kg body frequencies. weight bromazepam, but the subjects were allowed to http://gut.bmj.com/ sleep (11 tests on six subjects); (6) in this series, the SUBJECTS subjects were allowed to fall into a natural sleep. Six healthy students (four women and two men) who Sleep was facilitated by a uniform level of noise (12 were paid for their participation, were used as tests on six subjects); (7) in nine experiments subjects. They were aged from 21 to 29 years, the betazole was given by intravenous infusion during average being 22-9. natural sleep. Unfortunately, in all of these experi- ments, the subjects awoke eight to 15 minutes after on October 1, 2021 by guest. Protected copyright. PROCEDURE the start of the infusion. Therefore, the results of this The subjects came to the laboratory at 8.00 am series could not be used. after a 12-hour fast. The endoradiosonde, with a thin The experiments were continued for three hours silk thread attached to it, was swallowed and after but in three experiments the time was shorter for reaching the stomach, the thread was fixed to the technical reasons. In those experiments in which the subject's nose to prevent the pill from gliding further subjects were allowed to fall asleep, theywereawaken- 'downstream'. ed after two hours of sleep and the test was continued During the sessions, the subjects lay on a bed in a for another hour. supine or left-sided position. The results were analysed statistically by using After one hour of measuring basal acid secretion, Student's t test for paired values when comparing the following series of experiments was done: (1) data within the same series, and the t test for administration of 1.7 mg per kg body weight beta- unpaired values when comparing data from two zole subcutaneously (13 tests on six subjects); (2) different series. administration of 1.7 mg per kg body weight betazole (subcutaneously) plus 0.1 mg per kg body Results weight bromazepam intravenously. In this series, the subjects were kept awake (10 tests on six subjects); Acid output during the basal hour was in the same (3) as in series 2, but the subjects were allowed to range in all six series. The level of basal secretion in sleep after receiving the drugs (11 tests on six our experiments was somewhat higher than in Gut: first published as 10.1136/gut.15.2.116 on 1 February 1974. Downloaded from 118 G. Stacher and Doris Starker Fig 2a Acid output (m-equiv/15 minutes), mean i 1 standard error of mean, for series 1, 2, 3, 4, 5, and 6. The significance of the difference between each value after administration ofthe drug and the onset ofnatural sleep respectively (series 6) and the mean ofthe four basal quarter- hour outputs is indicated. x =P<0-05, xx,P<OOI, x x x,p < 0-001. 1 BETAZOLE+ BROM 10 N 1 5 http://gut.bmj.com/ 0 F-S L E E Fp l 7 .3 6 1 1 240 7l MIN. 0 60 120 180 240 on October 1, 2021 by guest. Protected copyright. secretion tests carried out by the tube technique. A first 15 minutes after the injections than in series 1. possible explanation of this fact is that since con- In the following periods acid secretion in series 2 tinuous intragastric titration involves frequent did not differ statistically from the values in series 1. stimulation of the antrum with bicarbonate, gastric secretion is stimulated by endogenous gastrin. SERIES 3 When the subjects fell asleep after the simultaneous SERIES 1 administration of betazole and bromazepam a sig- Administration of 1.7 mg per kg body weight nificant decrease (p < 0.05) of acid secretion during betazole subcutaneously led to a marked stimulation the first 15 minutes compared with the basal hour of acid secretion in all experiments which on the occurred. In the following periods even less acid average lasted for two hours after injection. was produced. The low level of secretory output was maintained as long as the individuals were asleep. SERIES 2 Wakening caused a highly significant increase Simultaneous administration of 1.7 mg per kg body (p < 0001) in the four 15-minute periods which weight betazole subcutaneously and 01 mg per kg followed sleep. Acid secretion during sleep was body weight bromazepam intraveously caused a significantly lower than in the corresponding periods significantly lower (p < 0.01) acid output during the of experiments in series 1 and 2 (fig 2a). Gut: first published as 10.1136/gut.15.2.116 on 1 February 1974. Downloaded from Inhibitory effect ofbromazepam on basal and betazole-stimulated gastric acid secretion in man 119 Fig 2b Acid output (m-equiv/15 minutes), mean ± 1 standard error ofmean, for series 1, 2, 3, 4, 5, and 6. The significance of the difference between each value after administration of the drug and the onset ofnatural sleep respectively (series 6) and the mean of the four basal quarter- hour outputs is indicated. x =p < 0'05, x X, P < 0-01, x x X,P < 0001, http://gut.bmj.com/ SERIES 4 SERIES 6 Administration of bromazepam alone caused a After the onset of natural sleep, as in series 3 and diminution of acid secretion compared with the 5, gastric acid secretion declined sharply and basal period.
Load more

Recommended publications
  • ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0
    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0 USER MANUAL December 2020 Department of Veterans Affairs Office of Information and Technology (OIT) Product Development Revision History Date Description (Patch # if applicable) Project Manager Technical Writer 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx Claims Report ePharmacy ePharmacy Screen Display Development TeamDevelopment Team Updated Title Page date and footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx. 05/2017 Updated for BPS*1*21 REDACTED REDACTED 08/2016 Updated for BPS*1*20 REDACTED
    [Show full text]
  • Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW
    Guideline Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW Summary To provide the most up-to-date knowledge and current level of best practice for the treatment of withdrawal from alcohol and other drugs such as heroin, and other opioids, benzodiazepines, cannabis and psychostimulants. Document type Guideline Document number GL2008_011 Publication date 04 July 2008 Author branch Centre for Alcohol and Other Drugs Branch contact (02) 9424 5938 Review date 18 April 2018 Policy manual Not applicable File number 04/2766 Previous reference N/A Status Active Functional group Clinical/Patient Services - Pharmaceutical, Medical Treatment Population Health - Pharmaceutical Applies to Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations, Affiliated Health Organisations - Declared Distributed to Public Health System, Ministry of Health, Public Hospitals Audience All groups of health care workers;particularly prescribers of opioid treatments Secretary, NSW Health Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW space Document Number GL2008_011 Publication date 04-Jul-2008 Functional Sub group Clinical/ Patient Services - Pharmaceutical Clinical/ Patient Services - Medical Treatment Population Health - Pharmaceutical
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • Retention Behaviour of Some Benzodiazepines in Solid-Phase Extraction Using Modified Silica Adsorbents Having Various Hydrophobicities
    ACADEMIA ROMÂNĂ Rev. Roum. Chim., Revue Roumaine de Chimie 2015, 60(9), 891-898 http://web.icf.ro/rrch/ RETENTION BEHAVIOUR OF SOME BENZODIAZEPINES IN SOLID-PHASE EXTRACTION USING MODIFIED SILICA ADSORBENTS HAVING VARIOUS HYDROPHOBICITIES Elena BACALUM,a Mihaela CHEREGIb,* and Victor DAVIDb,* a Research Institute from University of Bucharest – ICUB, 36-46 M. Kogalniceanu Blvd., Bucharest, 050107, Roumania b University of Bucharest, Faculty of Chemistry, Department of Analytical Chemistry, 90 Panduri Ave, Bucharest – 050663, Roumania Received April 6, 2015 The retention properties of six benzodiazepines (alprazolam, bromazepam, diazepam, flunitrazepam, medazepam, and nitrazepam) on four different solid phase extraction silica 1.0 adsorbents with various hydrophobicities (octadecylsilica, octylsilica, phenylsilica, and cyanopropylsilica) were 0.8 H O investigated. The breakthrough curves showed a significant N retention of these compounds on octadecylsilica, octylsilica, 0.6 Br N phenylsilica, excepting alprazolam that has a poor retention on 0 C/C N octadecylsilica. These results can be explained by the 0.4 PHENYL CN hydrophobic character of studied benzodiazepines (octanol- C18 0.2 C8 Bromazepam water partition constant, log Kow, being situated within the interval 1.90-4.45). A poor retention on cyanopropylsilica was 0.0 observed for all studied compounds indicating that π-π and 0 102030405060708090100 Volume (mL) polar intermolecular interactions have a less significant role in their retention on this adsorbent. Generally, the breakthrough
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Electronic Claims Management Version 1.0 Engine User Manual
    Electronic Claims Management Engine (ECME) Version 1.0 User Manual May 2021 Department of Veterans Affairs Office of Information and Technology (OIT) Revision History Description (Patch # if Date Project Manager Technical Writer applicable) 05/2021 Updated for BPS*1*28 MCCF EDI TAS MCCF EDI TAS Updated Title Page date and ePharmacy ePharmacy footers Development Development Added Section 6.3.3 SC Team Team Prescriptions for Active Duty Prescriptions Added Section 8.1.11 Duplicate Claims Report 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx ePharmacy ePharmacy Claims Report Screen Display Development Development Updated Title Page date and Team Team footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option Electronic Claims Management Engine V. 1.0 User Manual ii May 2021 Description (Patch # if Date Project Manager Technical Writer applicable) 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx.
    [Show full text]
  • Pentameric Ligand-Gated Ion Channel ELIC Is Activated by GABA And
    Pentameric ligand-gated ion channel ELIC is activated PNAS PLUS by GABA and modulated by benzodiazepines Radovan Spurnya, Joachim Ramerstorferb, Kerry Pricec, Marijke Bramsa, Margot Ernstb, Hugues Nuryd, Mark Verheije, Pierre Legrandf, Daniel Bertrandg, Sonia Bertrandg, Dennis A. Doughertyh, Iwan J. P. de Esche, Pierre-Jean Corringerd, Werner Sieghartb, Sarah C. R. Lummisc, and Chris Ulensa,1 aDepartment of Cellular and Molecular Medicine, Laboratory of Structural Neurobiology, Catholic University of Leuven, 3000 Leuven, Belgium; bDepartment of Biochemistry and Molecular Biology of the Nervous System, Medical University of Vienna, A-1090 Vienna, Austria; cDepartment of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom; dPasteur Institute, G5 Group of Channel-Receptor, Centre National de la Recherche Scientifique, 75724 Paris, France; eDepartment of Medicinal Chemistry, VU University Amsterdam, 1081 HV, Amsterdam, The Netherlands; fSOLEIL Synchrotron, 91192 Gif sur Yvette, France; gHiQScreen, CH-1211 Geneva, Switzerland; and hCalifornia Institute of Technology, Pasadena, CA 91125 Edited* by Jean-Pierre Changeux, Institut Pasteur, Paris Cedex 15, France, and approved September 10, 2012 (received for review May 24, 2012) GABAA receptors are pentameric ligand-gated ion channels in- marized in SI Appendix, Table S1). In addition, it has been volved in fast inhibitory neurotransmission and are allosterically suggested that the GABA carboxylate group is stabilized through modulated by the anxiolytic, anticonvulsant, and sedative-hypnotic electrostatic interactions with Arg residues on the principal and benzodiazepines. Here we show that the prokaryotic homolog ELIC complementary faces of the binding site (4, 7–9). For benzo- also is activated by GABA and is modulated by benzodiazepines diazepines, the individual contributions of residues in loops A–F with effects comparable to those at GABAA receptors.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Evidence-Based Guidelines for the Pharmacological Management of Substance Abuse, Harmful Use, Addictio
    444324 JOP0010.1177/0269881112444324Lingford-Hughes et al.Journal of Psychopharmacology 2012 BAP Guidelines BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, Journal of Psychopharmacology 0(0) 1 –54 harmful use, addiction and comorbidity: © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav recommendations from BAP DOI: 10.1177/0269881112444324 jop.sagepub.com AR Lingford-Hughes1, S Welch2, L Peters3 and DJ Nutt 1 With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A Abstract The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Keywords Substance misuse, addiction, guidelines, pharmacotherapy, comorbidity Introduction guidelines (e.g.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Possible Modulation of Neurobehavioural Patterns by Anxiolytics Drugs
    Zaved Ahmed Khan et al. / International Journal of Pharma Sciences and Research (IJPSR) Vol.1(11), 2010, 457-464 Possible modulation of neurobehavioural patterns by anxiolytics drugs Zaved Ahmed Khan ,FICER (Corresponding Author) Assistant Professor Medical Biotechnology Division School of Biosciences and Technology, VIT University, Vellore-632014 TN, India Dr Asit Ranjan Ghosh Professor Medical Biotechnology Division School of Biosciences and Technology, VIT University, Vellore-632014 TN, India ABSTRACT Stress is very common and affects as many as one in eight every people in their teen years. Depression, which is common form of stress related disorder affects people of every color, race, economic status, or age. However, it does seem to affect more females than males during adolescence and adulthood. Stress affects mind, body, and behavior in many ways. The signs and symptoms of stress vary from person to person, but all have the potential to harm our health, emotional wellbeing, and relationships with others. The stress response of the body is meant to protect and support us in maintaining stability. Our body is constantly adjusting to its surroundings. When a physical or mental event threatens this equilibrium, we react to it. Anxiety is characterized by a persistent and disproportionate fear unrelated to any genuine risk. It can increase to an extent that may interfere with even normal routine of life and person may feel apprehensive regarding happenings of normal things in life. The present paper discusses anti-anxiety potential of 15 anxiolytics with emphasis on their pre-clinical and clinical reports.majority of drugs have been found to be acting through modulation of serotonin and gamma butyric acid (GABA) neurotransmitters.
    [Show full text]